Even after treatments pass Health Canada’s review, getting them publicly reimbursed here takes longer than any other G7 country

It was nearly two years ago when an oncologist first told Jas Velic that his best hope of surviving aggressive blood cancer was CAR-T therapy, a cutting-edge treatment that would genetically alter some of his own white blood cells to attack his cancer.

Unlike the punishing regimen of weekly chemotherapy keeping the 43-year-old father of two alive, CAR-T therapy is given as a single infusion.

From The Globe and Mail via this RSS feed